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Viruses often evolve resistance to antiviral agents. While resistant strains are able to replicate in the
presence of the agent, they generally exhibit lower fitness than the wild-type strain in the absence of the
inhibitor. In some cases, resistant strains become dependent on the antiviral agent. However, the agent rarely,
if ever, elevates dependent strain fitness above the uninhibited wild-type level. This would require an adaptive
mechanism to convert the antiviral agent into a beneficial growth factor. Using an inhibitory scaffolding protein
that specifically blocks X174 capsid assembly, we demonstrate that such mechanisms are possible. To obtain
the quintuple-mutant resistant strain, the wild-type virus was propagated for approximately 150 viral life cycles
in the presence of increasing concentrations of the inhibitory protein. The expression of the inhibitory protein
elevated the strain’s fitness significantly above the uninhibited wild-type level. Thus, selecting for resistance
coselected for dependency, which was characterized and found to operate on the level of capsid nucleation. To
the best of our knowledge, this is the first report of a virus evolving a mechanism to productively utilize an
antiviral agent to stimulate its fitness above the uninhibited wild-type level. The results of this study may be
predictive of the types of resistant phenotypes that could be selected by antiviral agents that specifically target
capsid assembly.
While viruses often acquire resistance to antiviral agents,
resistance mutants generally exhibit lower fitness than the wild-
type strain in the absence of the inhibitor (6, 16, 17, 25) and can
develop a dependency on the antiviral agent (1, 19). However,
the molecular mechanism of dependency rarely, if ever, in-
volves the productive use of the antiviral agent to elevate
fitness above the uninhibited wild-type level. Many studies are
conducted with animal viruses, often in clinical settings, which
can impose restraints on the experimental durations. Thus,
prolonged exposure to antiviral agents may be required for the
emergence of a multiply mutant strain that has evolved mech-
anisms to productively utilize inhibitors.
Due to its rapid replication, bacteriophage X174 has be-
come an attractive model system for evolutionary studies (2, 3,
23, 24). Selective pressures can be applied for hundreds of
infection cycles in a relatively short period of time. Using the
atomic structure of assembly intermediates as a guide (8, 9,
15), viral scaffolding proteins that inhibit virion assembly have
been designed (4). The molecular mechanism of inhibition was
characterized, and resistance mutants were isolated via one-
step genetic selections (4). In this study we report the isolation
of a more robust resistant mutant. The quintuple mutant was
generated by propagating X174 for approximately 150 life
cycles in the presence of increasing concentrations of the in-
hibitory protein, which was derived from the external scaffold-
ing D protein. This protein forms asymmetric dimers that di-
rect procapsid assembly. A conformational switch at glycine
residue 61 (G61) in -helix 3 is critical for productive dimer
formation. In one subunit, -helix 3 is bent 30°, whereas it
assumes a straight conformation in the other subunit. All
amino acid substitutions for G61 inhibit the ability to undergo
the requisite conformational switch. The severity of the con-
ferred dominant lethal phenotypes directly correlates with the
side chain sizes of the substituted amino acids (4, 5).
The inhibitory proteins most likely remove assembly inter-
mediates by lowering the thermodynamic barriers that nor-
mally prevent off-pathway reactions (4, 5). Both off-pathway
reactions and proper assembly involve D-D protein interac-
tions across what will become the twofold axes of symmetry in
the virion (8, 9). In the procapsid crystal structure, -helix 3 of
the D2, D3, and D4 subunits mediates these interactions. Mu-
tants resistant to the dominant lethal proteins were isolated in
one-step genetic selections, and mutations mapped to either
the coat or internal scaffolding proteins. These mutations may
indirectly reinstate the avidity of the D protein electrostatic
bonding partners required for productive morphogenesis (4,
5). However, the resistance phenotype is weak. To isolate a
more robust phenotype, wild-type X174 was continually cul-
tured through exponential phase cells expressing an inhibitory
D protein. Results from this analysis indicate that the selection
for resistance coselected for a level of dependence. The inhib-
itory protein stimulates resistant strain fitness significantly
above the uninhibited wild-type level and appears to be re-
quired for efficient capsid nucleation. These results suggest
that the virus evolved a mechanism to convert this potent
antiviral agent into a beneficial factor and may be predictive of
the types of resistant phenotypes that could be selected by
antiviral agents that specifically target capsid assembly.
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Phage plating, media, buffers, and stock preparation. The reagents, media,
buffers, and protocols have been previously described (11).
Bacterial strains, phage strains, and plasmids. The Escherichia coli C strains
C122 (sup0) and BAF30 (recA) have been previously described (11, 12). The host
cell slyD mutation confers resistance to E protein-mediated lysis (18). The con-
struction of the cloned wild-type and inhibitory D genes, pND and pG61D,
respectively, has been previously reported (4).
Evolution of a more robust resistance phenotype. BAF30 pG61D and BAF30
pND cells were grown to a concentration of 1.0  108 cells/ml at 37°C in TK
medium supplemented with 20 g/ml of ampicillin. Cells were concentrated
100-fold, resuspended in 30% glycerol, and frozen at 80°C. Prior to infection,
10 ml of TK medium with 20 g/ml ampicillin was inoculated with 25 l of frozen
cells and incubated with aeration for 1 h in a 125-ml flask, at which time the cells
were in exponential phase. MgCl2 and CaCl2 were added to respective concen-
trations of 10 mM and 0.5 mM. Cells were infected at a multiplicity of infection
(MOI) of less than 0.01 and incubated at 37°C for 40 min. An aliquot of the
infection culture was then used to inoculate a fresh flask of exponential cells.
After each passage, titers of the cultures were determined to calculate approx-
imate fitness, and plaque morphologies were noted on cells expressing the in-
hibitory protein. A portion of each infection culture was frozen at 80°C. If titers
indicated that infections were conducted at an MOI above 0.01, all further
passages were discarded. The concentration of the inducer, IPTG (isopropyl--
D-thiogalactopyranoside), varied during passages. When it appeared that a se-
lective sweep had occurred in the population, the induction level of the cloned
gene was increased.
Fitness assays. The protocol for the fitness assays and the calculation of fitness
have been previously described (3). Fitness is expressed as doublings per hour.
Determination of D protein expression levels. To determine levels of mutant
G61D external scaffolding protein expression, a 20-ml culture of TK medium,
supplemented with 20 g/ml ampicillin and IPTG at concentrations varying from
0 to 1.3 mM, was inoculated at 1/100 with a fresh overnight culture of lysis-
resistant cells and grown to a concentration of 1.0  108 cells/ml. Cells were
infected with either wild-type or nullD X174 at an MOI of 3.0 and incubated for
1 h; cells were then concentrated, resuspended in 0.8 ml of 20 mM Tris-HCl (pH
8.0), boiled, and subjected to sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis. Band intensity was analyzed with ImageJ software (NIH). The relative
level of G61D protein expression was estimated by comparison with wild-type-
and nullD-infected cells, with and without exogenous D protein expression.
Attachment and eclipse assays. Attachment assays were performed as previ-
ously described (13). The protocol for the eclipse assay was modified from a
previously published protocol (14). Exponential cells were concentrated and
resuspended in HFB buffer with 10 mM MgCl2 and 0.5 mM CaCl2. After
infection, samples were incubated at 10°C for 30 min. Unattached virions were
removed by centrifugation. The cell pellets with attached phage were resus-
pended in 1.0 ml of ice-cold HFB with 10 mM MgCl2 and 0.5 mM CaCl2 and
placed into a 37°C water bath to initiate the eclipse reaction. At selected time
points, samples were diluted 1/10 in borate-EDTA buffer, which releases un-
eclipsed phages from cell membranes, and titers were determined for surviving
particles.
In vivo characterization of the morphogenetic pathway and the kinetics of
virus production. The protocols for generating extracts of infected lysis-resistant
cells, ultracentrifugation parameters, particle (virions, procapsid, and degraded
procapsid) detection, and in vivo kinetics have been previously described
(20, 21).
RESULTS
Generation of the multiply mutant resistant strain. To
evolve the multiply mutant resistant strain, wild-type X174
was continuously cultured in exponential phase E. coli BAF30
(recA) cells expressing the strongly inhibitory G61D external
scaffolding D protein for 59 40-min passages. As a control,
X174 was cultured through cells expressing the wild-type D
protein. To minimize other possible selective pressures, all
passages were conducted at a low MOI. During the first eight
passages, the cloned gene, under lac induction, was expressed
at a low level, one that reduced fitness to approximately one-
half that observed in cells not expressing the inhibitory protein.
Throughout the course of the experiment, fitness was mea-
sured, and plaque morphologies were observed on cells ex-
pressing the inhibitory protein. When it appeared that fitness
had increased, indicative of a selective sweep of at least one
beneficial mutation, the induction level of the cloned inhibitory
gene was increased. In parallel, the induction of the cloned
wild-type gene was increased in the control cultures; however,
the fitness of that control population remained constant
throughout the experiment. After 24 passages, the expression
of the cloned gene reached its maximal level, resulting in ap-
proximately 1:1 mutant-to-wild-type protein ratios (20). Once
the passages were completed, the entire genome sequence of
an aliquot from each population was determined to reveal all
mutations that had swept to high frequency. The population
cultured through cells expressing the wild-type D protein ac-
quired a single mutation in amino acid 100 of the coat protein.
However, five different mutations were identified in the pop-
ulation cultured in cells expressing the inhibitory protein.
These mutations mapped to the coat, DNA pilot, and external
scaffolding proteins (Table 1).
The fitness and phenotype of the resistant strain. To elim-
inate complications associated with assaying the fitness of a
mixed population, single plaques were isolated and sequenced
to identify a strain containing all five mutations listed in Table
1. Fitness assays for the ancestor and evolved strains were
conducted in BAF30 cells without the cloned inhibitory gene
and in cells expressing various levels of the inhibitory G61D
external scaffolding protein (Fig. 1). All assays were conducted
in replicates of five and analyzed to determine statistical sig-
nificance (GraphPad Prism software). BAF30 is a recA deriv-
ative of E. coli C122, in which the ancestral strain has been
propagated for over 40 years. The recA cell line was used for
continuous culturing to minimize possible recombination
events between the phage and plasmid. The fitness of the
ancestral strain was lower in BAF30 (9.4  0.3 doublings/h)
than in E. coli C122 (19.9  0.6 doublings/h).
The evolved strain was significantly more fit than the ances-
tor in the presence of the inhibitory protein but had lower
fitness in its absence (Fig. 1). Ancestral strain fitness decreased
with increased inhibitory protein expression. However, the
evolved strain exhibited optimal fitness when the inhibitory
protein was expressed at approximately 25% of the native
species (see below). Thus, selecting for resistance coselected
for a level of dependence.
To determine the relative level of mutant D protein required
to promote optimal fitness, protein levels were examined in
wild-type lysis-resistant infected cells. Infections were con-
TABLE 1. The mutations identified within the multiply mutant
resistant strain
Nucleotide
substitution Conferred amino acid substitution
Position Change Protein type Position Change
493 A3G External scaffolding 34 Asp3Gly
1133 G3C Coat 44 Asp3His
1616 G3A Coat 205 Asp3Asn
1682 T3C Coat 227 Ser3Pro
3340 A3G DNA pilot 136 Asp3Gly
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ducted with and without the plasmid encoding the inhibitory
protein. IPTG concentrations varying from 0 to 1.3 mM were
used to control cloned gene expression. Whole-cell lysates
were subjected to sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (Fig. 2), and the gels were analyzed by ImageJ
software (NIH). The major spike protein G served as an in-
ternal control for each infection, allowing the relative D/G
protein ratios to be determined. To estimate the levels of D
protein expressed from the plasmid, D/G protein ratios from
infections in cells with the induced cloned gene were compared
to the D/G protein ratio obtained from infected cells without
the plasmid. No significant differences in D protein levels were
observed between the infection without the plasmid and the
infection with an uninduced cloned gene. IPTG concentrations
of 0.5 and 1.3 mM resulted in 25% and 100% increases, re-
spectively, in total D protein levels. The results of experiments
conducted with the nullD mutant yielded similar results (data
not shown).
Molecular basis of the resistance phenotype. Although the
primary selective pressure was most likely the expression of
the inhibitory scaffolding protein, which would affect assembly,
the contribution of other selective pressures cannot be elimi-
nated a priori. Therefore, the ancestral and evolved strains
were characterized for attachment and eclipse efficiency. No
significant differences in attachment kinetics were observed
(data not shown). In eclipse assays, conducted in triplicate, the
evolved strain exhibited modestly faster kinetics (Fig. 3). This
benefit is likely conferred by the substitution in the DNA pilot
protein.
Mutant D proteins are known to affect the timing of pro-
capsid nucleation and the rate of virion assembly in vivo (5, 20,
22). To determine if the evolved strain had altered assembly
kinetics, the time course of phage production was followed in
lysis-resistant cells with and without inhibitory gene induction.
The cloned gene was induced at the level that promoted opti-
mal fitness (Fig. 1). In these experiments phage were preat-
tached to lysis-resistant cells, and unattached particles were
removed by centrifugation. Infections commenced at time
zero, which represents the beginning of the irreversible eclipse
reaction. At each time point, aliquots of the infection were
removed and chemically lysed, and titers were determined for
progeny production. The low level of phage detected during
the lag phase most likely represents uneclipsed virions. As can
be seen in Fig. 4, induction of the inhibitory D gene resulted in
the faster appearance and increased production of progeny. In
FIG. 1. Fitness values for the ancestral (black box) and multiply
mutant resistant (white box) strains. Fitness is measured as doublings
per hour. Cells containing plasmids were induced to express the cloned
D protein with 0.5 and 1.3 mM IPTG concentrations. All infections
were conducted at low MOIs and in replicates of five.
FIG. 2. Expression levels of the inhibitory G61D external scaffolding protein in wild-type-infected cells. Lane 1, infected cells and no plasmid;
lane 2, infected cells with pG61D and no IPTG; lane 3, infected cells with pG61D and 0.5 mM IPTG; lane 4, infected cells with pG61D and 1.3
mM IPTG; lane 5, molecular mass marker; lane 6, BAF30 cells expressing wild-type D protein; lane 7, BAF30 cells without a plasmid; lane 8,
purified viral proteins B and G.
FIG. 3. Eclipse kinetics of ancestral (filled squares) and evolved
(empty circles) strains.
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the absence of inhibitory gene induction, the longer lag phase
and decreased yield could reflect less efficient procapsid nu-
cleation or DNA packaging. Defects in DNA packaging result
in the accumulation of procapsids and empty particles (10, 21).
To determine if these particles were accumulating, extracts
prepared from infected cells with and without inhibitory gene
induction were analyzed by rate zonal sedimentation. Neither
procapsids nor empty particles were observed (data not
shown). These data indicate that the evolved strain is depen-
dent on the inhibitory protein for efficient procapsid nucle-
ation.
DISCUSSION
As observed in other studies, acquiring resistance to an
antiviral agent lowered strain fitness vis-à-vis the uninhibited
wild-type levels (6, 16, 25). The acquisition of compensatory
mutations occasionally restores replication capacity (7), and
coselection for dependence on the antiviral chemical com-
pounds has been documented (1, 19). However, to the best of
our knowledge this represents the first documentation of a
virus’s evolving a mechanism to productively utilize an antiviral
agent to stimulate its fitness at a level substantially higher than
the uninhibited wild-type level. Furthermore, the results of this
study may be predictive of the types of resistance phenotypes
that could be selected in the presence of antiviral agents that
specifically target capsid assembly.
Wild-type X174 was evolved in cells expressing an inhibi-
tory external scaffolding D protein for approximately 150
phage generations. The evolved strain acquired five mutations,
mapping to the coat, external scaffolding, and DNA pilot pro-
teins. In contrast, only one unrelated coat protein mutation
was identified when the ancestral strain was cultured in cells
expressing the wild-type D protein. This coat protein mutation,
which was not present in the evolved strain, was previously
identified in another evolutionary study in which the only se-
lective pressure was the ability to compete within the popula-
tion (23). Evidence that the adaptation is primarily to the
inhibitory protein and not to the recA cells includes the ab-
sence of fitness increase in the control line and the reduced
fitness of the evolved virus in the absence of the inhibitor.
Thus, the expression of the inhibitory protein imposed the
primary selective pressure in these experiments.
The fitness of the ancestral and evolved strains was deter-
mined. While ancestral strain fitness decreased as a function of
increased inhibitory gene induction, the fitness of the evolved
strain dramatically increased. Optimal fitness was observed
when the inhibitory protein was present at a concentration
equal to approximately 25% of the indigenous protein. The
inhibitory protein appears to stimulate the faster appearance
and increased production of progeny. As there is no temporal
gene expression in X174, the reduced lag phase before prog-
eny production most likely represents more efficient procapsid
nucleation (5, 20, 22).
The location of the identified coat protein mutations is rem-
iniscent of mutations observed in previous studies (4). The
S227P mutation was isolated in one-step selections, and the
D44H site is directly adjacent to a previously identified resis-
tance mutation in the atomic structure. Thus far, all mutations
involved in resistance reside under the D3 subunit in the pro-
capsid lattice. This clustering may indicate that the evolved
strain has tailored a coat protein region to accommodate mu-
tant external scaffolding proteins. However, the resistance phe-
notype is not allele specific. The multiply mutant strain is
resistant to all previously identified inhibitory proteins (4),
including one with a G3P substitution (data not shown).
While other substitutions would restrict the bending of -helix
3, a proline substitution would lock it in a kinked position.
Thus, it is difficult to conceive of a model in which a region of
the coat protein is becoming structurally specialized.
As the inhibitory proteins are known to promiscuously pro-
mote off-pathway reactions (4, 5), the coat protein resistance
mutations may produce early assembly intermediates that are
less prone to associate with scaffolding subunits, both wild type
and inhibitory. The dependency phenomenon appears to op-
erate on the level of capsid nucleation. Therefore, efficient
nucleation may now depend on a small concentration of the
more reactive inhibitory proteins. The acquired mutation in
the genome-encoded external scaffolding protein may alleviate
defects in the capsid elongation reaction. The mutation confers
a D 3 G substitution in -helix 2. As this particular helix
mediates no contacts with other structural or scaffolding pro-
teins, the substitution may provide an alternative locus for
conformational flexibility, which compensates for the steric
hindrance introduced into -helix 3. Regardless of the exact
mechanism, the virus has evolved a means to productively
incorporate an antiviral agent into its life cycle.
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